Lupin receives final approval for Nystatin and Triamcinolone Acetonide Cream USP

04 Jun 2018 Evaluate

Lupin has received final approval for its Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1mg/gram, from the United States Food and Drug Administration (USFDA) to market a generic version of Delcor Asset Corporation’s (Delcor) Mycolog-II Cream.

Lupin’s Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1mg/gram, is the generic equivalent of Delcor’s Mycolog-II Cream. It is indicated for the treatment of cutaneous candidiasis. Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1mg/gram, had annual sales of approximately $ 62.2 million in the US (IQVIA MAT April 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2137.15 -27.90 (-1.29%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×